223 related articles for article (PubMed ID: 24215488)
1. Osteopontin is a prognostic biomarker in non-small cell lung cancer.
Rud AK; Boye K; Oijordsbakken M; Lund-Iversen M; Halvorsen AR; Solberg SK; Berge G; Helland A; Brustugun OT; Mælandsmo GM
BMC Cancer; 2013 Nov; 13():540. PubMed ID: 24215488
[TBL] [Abstract][Full Text] [Related]
2. Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.
Rud AK; Lund-Iversen M; Berge G; Brustugun OT; Solberg SK; Mælandsmo GM; Boye K
BMC Cancer; 2012 Aug; 12():333. PubMed ID: 22853000
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
4. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.
Sun BS; Li Y; Zhang ZF; You J; Wang CL
Ann Thorac Surg; 2013 Dec; 96(6):1943-51. PubMed ID: 24094519
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.
Chang YS; Kim HJ; Chang J; Ahn CM; Kim SK; Kim SK
Lung Cancer; 2007 Sep; 57(3):373-80. PubMed ID: 17513004
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.
Jin Y; Tong DY; Chen JN; Feng ZY; Yang JY; Shao CK; Li JP
PLoS One; 2012; 7(10):e48575. PubMed ID: 23119061
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer.
Miao S; Qiu T; Zhao Y; Wang H; Sun X; Wang Y; Xuan Y; Qin Y; Jiao W
Thorac Cancer; 2018 Sep; 9(9):1136-1144. PubMed ID: 30047626
[TBL] [Abstract][Full Text] [Related]
12. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
13. Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer.
Feng YH; Su YC; Lin SF; Lin PR; Wu CL; Tung CL; Li CF; Shieh GS; Shiau AL
BMC Cancer; 2019 Aug; 19(1):791. PubMed ID: 31399076
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.
Zhang T; Zhang DM; Zhao D; Hou XM; Liu XJ; Ling XL; Ma SC
J Mol Histol; 2014 Oct; 45(5):533-40. PubMed ID: 24816798
[TBL] [Abstract][Full Text] [Related]
15. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.
Hao C; Cui Y; Chang S; Huang J; Birkin E; Hu M; Zhi X; Li W; Zhang L; Cheng S; Jiang WG
Sci Rep; 2019 Dec; 9(1):18101. PubMed ID: 31792339
[TBL] [Abstract][Full Text] [Related]
16. Regulatory roles of osteopontin in human lung cancer cell epithelial-to-mesenchymal transitions and responses.
Shi L; Hou J; Wang L; Fu H; Zhang Y; Song Y; Wang X
Clin Transl Med; 2021 Jul; 11(7):e486. PubMed ID: 34323425
[TBL] [Abstract][Full Text] [Related]
17. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Ostheimer C; Bache M; Güttler A; Kotzsch M; Vordermark D
Strahlenther Onkol; 2014 Mar; 190(3):276-82. PubMed ID: 24322994
[TBL] [Abstract][Full Text] [Related]
18. [Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer].
Chen XL; Wang LC; Zhang WG; Chen XY; Sun ZM
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1254-8. PubMed ID: 18676277
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and clinicopathological value of osteopontin expression in non-small cell lung cancer: a meta-analysis and systematic review.
Song Y; Li H; Jiang Q; Wu L
Biomarkers; 2024 Mar; 29(2):105-113. PubMed ID: 38376506
[TBL] [Abstract][Full Text] [Related]
20. [Inverse correlation of S100A4 and E-cad protein expression and their clinical significance in non-small cell lung cancer].
Qi RX; Xu XY
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):681-4. PubMed ID: 18246798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
